ies with Cubicin to investigate whether it has an effect on the muscle, and to look at its safety and effectiveness in patients with kidney disease and in the elderly.
Further information
The European Commission granted a marketing authorisation valid throughout the European Union for Cubicin on 19 January 2006. The marketing authorisation holder is Novartis Europharm Limited. The marketing authorisation is valid for an unlimited period.
For more information about treatment with Cubicin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
This summary was last updated in 09-2010.
↑ back to table of contents ↑
Name
Cubicin 350 mg powder for solution for injection or infusion
Composition
Each vial contains 350 mg daptomycin.
One ml provides 50 mg of daptomycin after reconstitution with 7 ml of sodium chloride 9 mg/ml (0.9%) solution.
For a full list of excipients, see section 6.1.
Pharmaceutical Form
Powder for solution for injection or infusion
A pale yellow to light brown lyophilised powder.
Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!
